Literature DB >> 26891890

Nitric oxide signaling in human ovarian cancer: A potential therapeutic target.

Ahmed El-Sehemy1, Lynne-Marie Postovit2, YangXin Fu3.   

Abstract

Ovarian cancer is the leading cause of death due to gynecologic malignancies worldwide. Current therapy regimens are ineffective to treat advanced ovarian cancers, presenting a need to develop novel therapeutic strategies. Nitric oxide (NO) is a multifunctional gaseous molecule that is generated by cancer, stromal and endothelial cells and plays a multifaceted role in cancer biology through multiple mechanisms. Accumulating evidence suggests that NO signaling is involved in multiple aspects of ovarian cancer, including growth, apoptosis, cancer-stromal cell interaction, angiogenesis and response to chemotherapy. This review will discuss the experimental and clinical evidence of the involvement of NO signaling in ovarian cancer and the therapeutic potential of targeting NO signaling in ovarian cancer.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diagnostic marker; Nitric oxide; Ovarian cancer; Therapeutic target; iNOS

Mesh:

Substances:

Year:  2016        PMID: 26891890     DOI: 10.1016/j.niox.2016.02.002

Source DB:  PubMed          Journal:  Nitric Oxide        ISSN: 1089-8603            Impact factor:   4.427


  11 in total

Review 1.  The roles of S-nitrosylation and S-glutathionylation in Alzheimer's disease.

Authors:  Ryan R Dyer; Katarena I Ford; Renã A S Robinson
Journal:  Methods Enzymol       Date:  2019       Impact factor: 1.600

2.  A Prospective Analysis of Circulating Plasma Metabolites Associated with Ovarian Cancer Risk.

Authors:  Clary B Clish; Shelley S Tworoger; Oana A Zeleznik; A Heather Eliassen; Peter Kraft; Elizabeth M Poole; Bernard A Rosner; Sarah Jeanfavre; Amy A Deik; Kevin Bullock; Daniel S Hitchcock; Julian Avila-Pacheco
Journal:  Cancer Res       Date:  2020-01-22       Impact factor: 12.701

3.  Ponatinib exerts anti-angiogenic effects in the zebrafish and human umbilical vein endothelial cells via blocking VEGFR signaling pathway.

Authors:  Nana Ai; Cheong-Meng Chong; Weiting Chen; Zhe Hu; Huanxing Su; Guokai Chen; Queenie Wing Lei Wong; Wei Ge
Journal:  Oncotarget       Date:  2018-01-10

Review 4.  Novel Insights on the Role of Nitric Oxide in the Ovary: A Review of the Literature.

Authors:  Maria Cristina Budani; Gian Mario Tiboni
Journal:  Int J Environ Res Public Health       Date:  2021-01-22       Impact factor: 3.390

5.  Plasma Gelsolin Confers Chemoresistance in Ovarian Cancer by Resetting the Relative Abundance and Function of Macrophage Subtypes.

Authors:  Meshach Asare-Werehene; Hideaki Tsuyoshi; Huilin Zhang; Reza Salehi; Chia-Yu Chang; Euridice Carmona; Clifford L Librach; Anne-Marie Mes-Masson; Chia-Ching Chang; Dylan Burger; Yoshio Yoshida; Benjamin K Tsang
Journal:  Cancers (Basel)       Date:  2022-02-18       Impact factor: 6.639

6.  Preparation of a PEGylated liposome that co-encapsulates l-arginine and doxorubicin to achieve a synergistic anticancer effect.

Authors:  Haitao Feng; Jeong-Hun Kang; Song Qi; Akihiro Kishimura; Takeshi Mori; Yoshiki Katayama
Journal:  RSC Adv       Date:  2021-10-21       Impact factor: 3.361

Review 7.  Nitric oxide and pH modulation in gynaecological cancer.

Authors:  Carlos Sanhueza; Joaquín Araos; Luciano Naranjo; Eric Barros; Mario Subiabre; Fernando Toledo; Jaime Gutiérrez; Delia I Chiarello; Fabián Pardo; Andrea Leiva; Luis Sobrevia
Journal:  J Cell Mol Med       Date:  2016-07-29       Impact factor: 5.310

Review 8.  The regulation of nitric oxide in tumor progression and therapy.

Authors:  Ya Hu; Jing Xiang; Linlin Su; Xi Tang
Journal:  J Int Med Res       Date:  2020-02       Impact factor: 1.671

9.  Inhibition of livin overcomes radioresistance in nasopharyngeal carcinoma cells.

Authors:  Fei Ma; Xia Gu; Jiang-Qi Liu; Li-Hua Mo; Gui Yang; Xiao-Rui Geng; Zhi-Qiang Liu; Zhi-Gang Liu; Ping-Chang Yang
Journal:  PLoS One       Date:  2020-03-02       Impact factor: 3.240

Review 10.  Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets.

Authors:  Maria Sofia Basile; Emanuela Mazzon; Paolo Fagone; Antonio Longo; Andrea Russo; Matteo Fallico; Vincenza Bonfiglio; Ferdinando Nicoletti; Teresio Avitabile; Michele Reibaldi
Journal:  Front Oncol       Date:  2019-11-05       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.